The future of somatostatin analogue therapy

Bailliere's Best Practice and Research in Clinical Endocrinology and Metabolism

Volumn 13, Issue 3, 1999, Pages 409-418

  Stewart, Paul M ^a   James, R Andrew ^b  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

Acromegaly; Lanreotide; Octreotide; Pituitary; Somatostatin; Somatostatin analogue

Indexed keywords

ANGIOPEPTIN; GROWTH HORMONE; OCTREOTIDE; RECEPTOR SUBTYPE; SOMATOSTATIN; SOMATOSTATIN DERIVATIVE; SOMATOSTATIN RECEPTOR; THYROTROPIN;

ACROMEGALY; DRUG EFFICACY; HUMAN; HYPOPHYSIS ADENOMA; HYPOPHYSIS DISEASE; HYPOPHYSIS TUMOR; REVIEW; SCINTIGRAPHY; SIDE EFFECT;

EID: 0033510797     PISSN: 1521690X     EISSN: None     Source Type: Journal    
DOI: 10.1053/beem.1999.0031     Document Type: Article

References (58)

1. Brazeau P, Vale W, Burgus R. Hypothalamic polypeptide that inhibits the secretion of immunoreactive pituitary growth hormone. Science. 179:1973;77-79.
2. Pradayrol L, Jornvall H, Mutt V, Ribet A. N-terminally extended somatostatin: the primary structure of somatostatin-28. FEBS Letters. 109:1980;55-88.
3. Mandarino L, Stenner D, Blanchard W. Selective effects of somatostatin-14, 25 and 28 on in vitro insulin and glucagon secretions. Nature. 291:1981;76-77.
4. Srikant C B, Patel Y C. Somatostatin receptors in the rat adrenal cortex: characterization and comparison with brain and pituitary receptors. Endocrinology. 116:1985;1717-1723.
5. Weightman D R, Whitford C A, Snell C R. Rat brain membranes possess two high-affinity binding sites for [3H] somatostatin. Neuroscience Letters. 55:1985;161-166.
6. Reubi J C. Evidence for two somatostatin-14 receptor types in rat brain cortex. Neuroscience Letters. 49:1984;259-263.
7. Yamada Y, Post S R, Wang K. Cloning and functional characterization of a family of human and mouse somatostatin receptor expressed in brain, gastrointestinal tract and kidney. Proceedings of the National Academy of Sciences of the USA. 89:1992;251-255.
8. Yamada Y, Reisine T, Laws S F. Somatostatin receptors, an expanding gene family: cloning and functional characterization of human sstR3, a protein coupled to adenylyl cyclase. Molecular Endocrinology. 6:1992;2136-2142.
9. Yasuda K, Rens-Domiano S, Breder C D. Cloning of a novel somatostatin receptor, sstR3 coupled to adenylyl cyclase. Journal of Biological Chemistry. 267:1992;20422-20428.
10. Kluxen F W, Bruns C, Lubbert H. Expression cloning of a rat brain somatostatin receptor cDNA. Proceedings of the National Academy of Sciences of the USA. 89:1992;4618-4622.
11. Bruno J F, Xu Y, Song J, Berelowitz M. Molecular cloning and functional expression of a brain-specific somatostatin receptor. Proceedings of the National Academy of Sciences of the USA. 89:1992;11151-11155.
12. O'Carroll A M, Lolait S J, Konig M, Mahan L C. Molecular cloning and expression of a pituitary somatostatin receptor with preferential affinity for somatostatin 28. Molecular Pharmacology. 42:1992;939-946.
13. Yamada Y, Stoffel M, Espinosa R. Human somatostatin receptor genes: localization to human chromosomes 14, 17, and 22: and identification of simple tandem repeat polymorphisms. Genomics. 15:1993;449-452.
14. Lamberts S WJ, Krenning E P, Reubi J C. The role of somatostatin and its analogues in the diagnosis and treatment of tumours. Endocrine Reviews. 12:1991;450-482.
15. Schally A V. Oncological applications of somatostatin analogues. Cancer Research. 48:1988;6977-6985.
16. Katznelson L, Oppenheim D S, Coughlin J F. Chronic somatostatin analogue administration in patients with alpha-subunit-secreting pituitary tumours. Journal of Clinical Endocrinology and Metabolism. 75:1992;1318-1325.
17. Miller G M, Alexander J M, Bikkal H A. Somatostatin receptor subtype gene expression in pituitary adenomas. Journal of Clinical Endocrinology and Metabolism. 80:1995;1386-1392.
18. Panetta R, Patel Y C. Expression of mRNA for all five human somatostatin receptors (hSSTR1-5) in pituitary tumours. Life Sciences. 56:1995;333-342.
19. Greenman Y, Melmed S. Somatostatin receptor subtypes in pituitary tumours. Frontiers of Hormone Research. 20:1996;99-107.
20. Chanson P, Weintraub B D, Harris A G. Octreotide therapy for thyroid-stimulating hormone secreting pituitary adenomas. Annals of Internal Medicine. 119:1993;236-240.
21. Lamberts S W, Utterlinden P, Klijn J MG. The effect of the long-acting somatostatin analogue SMS 201-995 on ACTH secretion in Nelson's syndrome and Cushing's disease. Acta Endocrinologica. 120:1989;760-766.
22. Warnet A. The effect of somatostatin analogue on chiasmal dysfunction from pituitary macroadenomas. Journal of Neurosurgery. 71:1989;687-690.
23. Melmed S. Acromegaly. New England Journal of Medicine. 322:1990;966-977.
24. Alexander L, Appleton D, Hall R. Epidemiology of acromegaly in the Newcastle region. Clinical Endocrinology. 12:1980;71-79.
25. Bengtsson B, Eden S, Ernest I. Epidemiology and long-term survival in acromegaly. Acta Medica Scandinavica. 223:1988;327-335.
26. Wright A D, Hill D M, Lowy C, Fraser R T. Mortality in acromegaly. Quarterly Journal of Medicine. 39:1970;1-16.
27. Orme S M, McNally R JQ, Cartwright R A, Belchetz P E. Mortality and cancer incidence in acromegaly: a retrospective cohort study. Journal of Clinical Endocrinology and Metabolism. 83:1998;2730-2734.
28. Bates A S, Van't Hoff W, Jones J M, Clayton R N. An audit of outcome of treatment in acromegaly. Quarterly Journal of Medicine. 86:1993;293-299.
29. Swearingen B, Barker F G, Katznelson L. Long-term mortality after transsphenoidal surgery and adjunctive therapy for acromegaly. Journal of Clinical Endocrinology and Metabolism. 83:1998;3419-3426.
30. Abosch A, Tyrrell J B, Lamborn K R. Transsphenoidal microsurgery for growth hormone-secreting pituitary adenomas: initial outcome and long-term results. Journal of Clinical Endocrinology and Metabolism. 83:1998;3411-3418.
31. Fahlbusch R, Honeggar J, Buchfelder M. Surgical management of acromegaly. Endocrinology and Metabolism Clinics of North America. 21:1992;669-691.
32. Osman I A, James R A, Chatterjee S. Factors determining the long-term outcome of surgery for acromegaly. Quarterly Journal of Medicine. 87:1994;617-623.
33. Sheaves R, Jenkins P, Blackburn P. Outcome of transsphenoidal surgery for acromegaly using strict criteria for surgical cure. Clinical Endocrinology. 45:1996;407-413.
34. Ahmed S, Elsheikh M, Stratton I M. Outcome of transphenoidal surgery for acromegaly and its relationship to surgical experience. Clinical Endocrinology. 50:1999;561-568.
35. Gittoes N JL, Sheppard M C, Johnson A P, Stewart P M. Outcome of surgery for acromegaly in Birmingham - the experience of a single surgeon. Quarterly Journal of Medicine. 92:1999;741-745.
36. Abs R, Verhelst J, Maiter D. Cabergoline in the treatment of acromegaly: a study in 64 patients. Journal of Clinical Endocrinology and Metabolism. 83:1998;374-378.
37. Plewe G, Beyer J, Krause U. Long-acting and selective suppression of growth hormone secretion by somatostatin analogue SMS 201-995 in acromegaly. Lancet. ii:1984;782-784.
38. Lamberts S WJ, Uitterlinden P, Verschoor L. Long-term treatment of acromegaly with the somatostatin analogue SMS 201-995. New England Journal of Medicine. 313:1985;1576-1580.
39. Vance M L, Harris A G. Long-term treatment of 189 acromegalic patients with the somatostatin analog octreotide. Archives of Internal Medicine. 151:1991;1573-1578.
40. Sassolas G, Harris A G, James-Deider A. Long-term effect of incremental doses of the somatostatin analog SMS 201-995 in 58 acromegalic patients. Journal of Clinical Endocrinology and Metabolism. 71:1990;391-397.
41. Newman C B, Melmed S, Snyder P J. Safety and efficacy of long-term octreotide therapy of acromegaly: results of a multicenter trial in 103 patients - a clinical research center study. Journal of Clinical Endocrinology and Metabolism. 80:1995;2768-2775.
42. Christensen S E, Weeke J, Orskov H. Continuous subcutaneous pump infusion of somatostatin analogue SMS 201-995 versus subcutaneous injection schedule in acromegalic patients. Clinical Endocrinology. 29:1987;297-306.
43. Grossman A, Ross R, Wass J AH, Besser G M. Depot-bromocriptine treatment for prolactinomas and acromegaly. Clinical Endocrinology. 24:1986;231-238.
44. Flogstad A K, Halse J, Haldorsen T. Sandostatin-LAR in acromegalic patients: a dose-response study. Journal of Clinical Endocrinology and Metabolism. 80:1995;3601-3607.
45. Stewart P M, Kane K, Stewart S E. Depot long-acting somatostatin analog (Sandostatin-LAR) is an effective treatment for acromegaly. Journal of Clinical Endocrinology and Metabolism. 80:1995;3267-3272.
46. Lancranjan I, Atkinson A B. Results of a multicentre study with Sandostatin LAR in acromegalic patients. Pituitary. 1:1999;105-114.
47. Heron I, Thomas F, Dero M. Pharmacokinetics and efficacy of a long-acting formulation of the new somatostatin analog BIM 23014 in patients with acromegaly. Journal of Clinical Endocrinology and Metabolism. 76:1993;721-727.
48. Al-Maskari M, Gebbie J, Kendall-Taylor P. The effect of a new slow-release, long acting somatostatin analogue, lanreotide in acromegaly. Clinical Endocrinology. 45:1996;415-421.
49. Giusti M, Gussoni G, Cuttica C M, Giordano G. Effectiveness and tolerability of slow release lanreotide treatment in active acromegaly: six month report on an Italian Multicentre Study. Journal of Clinical Endocrinology and Metabolism. 81:1997;2089-2097.
50. Flogstad A K, Halse J, Bakke S T. Sandostatin-LAR in acromegalic patients: long-term treatment. Journal of Clinical Endocrinology and Metabolism. 81:1997;23-28.
51. Davies P H, Stewart S E, Lancranjan I. Long-term therapy with long-acting octreotide (Sandostatin-LAR) for the management of acromegaly. Clinical Endocrinology. 48:1998;311-316.
52. Caron P, Morange-Ramos I, Cogne M, Jaquet P. Three year follow-up of acromegalic patients treated with intramuscular slow-release lanreotide. Journal of Clinical Endocrinology and Metabolism. 82:1997;18-22.
53. Newman C B, Melmed S, George A. Octreotide as primary therapy for acromegaly. Journal of Clinical Endocrinology and Metabolism. 83:1998;3034-3049.
54. Oppizzi G, Cozzi R, Dallabonzana D. Scintigraphic imaging of pituitary adenomas: an in vivo evaluation of somatostatin receptors. Journal of Endocrinological Investigation. 21:1998;512-519.
55. Schmidt M, Scheidhauer K, Luyken C. Somatostatin receptor imaging in intracranial tumours. European Journal of Nuclear Medicine. 25:1998;675-686.
56. de Herder W W, Hofland L J, van der Lely A J, Lamberts S W. Peptide receptors in gut endocrine tumours. Baillière's Clinical Gastroenterology. 10:1996;571-587.
57. James R A, Weightman D R. Somatostatin receptors: types and classification in the pituitary. Endocrinologist (USA). 5:1995;55-60.
58. Baillet L, Ronci N, Epelbaum J. Expression of somatostatin receptor subtypes 2 and 5 in human prolactinomas. Proceedings of the American Endocrine Society. 1999;P2-490.